Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11999986 | 0.86 | KDM4E (0.67) | ALDH1A1MAPTPKMKDM4ESMN1; SMN2 | |
| SCHEMBL2793723 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPTPKMKDM4EGLA | |
| SCHEMBL5040366 | 0.82 | KDM4E (0.68) | ALDH1A1MAPTPKMKDM4EGLA | |
| SCHEMBL2798266 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPTPKMKDM4EGLA | |
| SCHEMBL5149436 | 0.76 | KDM4E (0.60) | KDM4EGLA | |
| SCHEMBL11968823 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MAPTPKMKDM4EGLA | |
| SCHEMBL12155648 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTPKMKDM4ESMN1; SMN2 | |
| SCHEMBL2797429 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPTPKMGLASMN1; SMN2 | |
| SCHEMBL15709048 | 0.75 | KDM4E (1.00) | ALDH1A1KDM4EGLAHPGDMEN1 | |
| SCHEMBL11192095 | 0.73 | KDM4E (0.67) | ALDH1A1KDM4EGLAHPGDAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | ALDH1A1 3142/4885MAPT 3361/4885PKM 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.